Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

/

MNKD

M

MannKind Corporation (MNKD)

NGM – Real vaqt narxi. Valyuta: USD

3.28

-0.08 (-2.38%)

Yopilishda: May 12, 2026, 4:00 PM EDT

3.31

+0.03 (1.02%)

Bozor oldidan: May 13, 2026, 4:05 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript

MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript

MannKind: It's Complicated

MannKind: It's Complicated

MannKind Corporation remains a Hold, as revenue growth is increasingly reliant on niche assets like Furoscix and faces margin pressure. United Therapeutics' launch of Tresmi threatens MNKD's Tyvaso DPI royalties, intensifying competitive risks and highlighting MNKD's junior partner status. Pipeline prospects, including MNKD-201 and ralinepag DPI, offer potential but face significant clinical, commercial, and competitive hurdles.

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

MannKind (MNKD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago.

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the first quarter of 2026, and provided a business update.

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, announced today that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after market close.

Videolar

No Data

There is no data to display

Press-relizlar

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reported financial results for the first quarter of 2026, and provided a business update.

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

MannKind Announces Settlement of Convertible Senior Notes

MannKind Announces Settlement of Convertible Senior Notes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock.

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Q4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix ® Q4 2025 net sales of $23M, +91% vs.